Coulter Partners was delighted to partner once more with ERYTECH Pharma (Nasdaq & Euronext: ERYP), to secure the appointment of Melanie Rolli, M.D., to its Board of Directors. ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells. Dr. Rolli has more than 15 years of experience in the global biopharmaceutical and biotechnology industry, including in both Europe and the United States, and the company intends to propose the ratification of her appointment at ERYTECH’s next General Meeting of Shareholders.
“We are very pleased to welcome Melanie to our Board of Directors,” commented Dr Jean-Paul Kress, Chairman of the Board of ERYTECH Pharma. “We look forward to working with her to develop ERYTECH’s business plans and strategy as ERYTECH advances its late-stage clinical programs and begins preparations for its transition into a commercial-stage company. I would like to thank Coulter Partners for their professional support in achieving this high-caliber appointment”
“I am delighted to be joining ERYTECH‘s Board of Directors,” said Dr. Rolli. “It is an exciting time for ERYTECH as its lead product eryaspase is progressing through a pivotal Phase 3 clinical trial in one of the largest unmet medical needs in oncology. I look forward to working closely with the Board and leadership team in supporting the Company’s plans.” Dr. Rolli currently serves as the Chief Executive Officer of PIQUR Therapeutics AG, a Basel, Switzerland-based clinical stage biotechology company dedicated to drug development of targeted therapies in various oncological and dermatological indications. Previously, she was at Novartis Pharmaceuticals AG for 14 years, where she held positions of increasing responsibilities across the Drug Development, Safety, and Medical Affairs functions. At Novartis, she spent eight years in the United States in global and local positions as the Medical Director in Primary Care, Respiratory, Women’s Health and Dermatology and Oncology franchises.
Prior to joining Novartis, she worked as a post-doctoral cancer research physician at SCRIPPS Research Institute for Molecular and Experimental Medicine in La Jolla, California, and as a clinicial and researcher in Germany.
Dr. Rolli graduated from the University of Heidelberg with a doctorate in medicine and pharmacology.
ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.
For more information about ERYTECH, please visit erytech.com
LSX - European Lifestars Awards
14 November 2022
Top global hires for large-cap, mid-cap and public companies
07 June 2022
Top hires for VC & PE portfolio companies Q4-2021
25 January 2022
Top hires for VC & PE portfolio companies Q2-2021
27 July 2021